Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

T47D breast cancer cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) AMPK (1) Androgen Receptor (2) AP-1 (1) Apoptosis (8) Bcl-2 Family (1) Biochemical Assay Reagents (1) Caspase (1) CDK (2) Discoidin Domain Receptor (1) Drug Derivative (1) E1/E2/E3 Enzyme (1) EGFR (1) Endogenous Metabolite (2) Estrogen Receptor/ERR (13) Ferroptosis (1) Glucocorticoid Receptor (1) HDAC (1) Histone Methyltransferase (1) Interleukin Related (1) Isotope-Labeled Compounds (1) LDLR (1) Legumain (1) Microtubule/Tubulin (2) MMP (2) mTOR (1) PI3K (4) Progesterone Receptor (1) PROTACs (5) Proteasome (1) RAR/RXR (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) STAT (2) Steroid Sulfatase (2) γ-secretase (1)
By Research Areas:	Cancer (40) Endocrinology (1) Metabolic Disease (3)

By Targets:

Akt (3)

AMPK (1)

Androgen Receptor (2)

AP-1 (1)

Apoptosis (8)

Bcl-2 Family (1)

Biochemical Assay Reagents (1)

Caspase (1)

CDK (2)

Discoidin Domain Receptor (1)

Drug Derivative (1)

E1/E2/E3 Enzyme (1)

EGFR (1)

Endogenous Metabolite (2)

Estrogen Receptor/ERR (13)

Ferroptosis (1)

Glucocorticoid Receptor (1)

HDAC (1)

Histone Methyltransferase (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

LDLR (1)

Legumain (1)

Microtubule/Tubulin (2)

MMP (2)

mTOR (1)

PI3K (4)

Progesterone Receptor (1)

PROTACs (5)

Proteasome (1)

RAR/RXR (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

STAT (2)

Steroid Sulfatase (2)

γ-secretase (1)

By Research Areas:

Cancer (40)

Endocrinology (1)

Metabolic Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: BCRP BRK Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3 VISTA BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19822

Elacestrant Maximum Cited Publications 17 Publications Verification RAD1901	Estrogen Receptor/ERR	Cancer
Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER ⁺ breast cancer cell lines in vitro and in vivo .

HY-113293B

Estrone sulfate sodium 3 Publications Verification	Endogenous Metabolite Estrogen Receptor/ERR	Metabolic Disease Cancer
Estrone sulfate sodium is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate sodium is also a substrate of the OATP1B3 transporter. Estrone sulfate sodium can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate sodium stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate sodium is applicable to breast cancer-related research .

HY-19822A

Elacestrant dihydrochloride Maximum Cited Publications 17 Publications Verification RAD1901 dihydrochloride	Estrogen Receptor/ERR	Cancer
Elacestrant (RAD1901) dihydrochloride is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant dihydrochloride also can inhibit growth of ER ⁺ breast cancer cell lines in vitro and in vivo .

HY-175465

SMI-10B13	Interleukin Related STAT	Cancer
SMI-10B13 is an Oncostatin M (OSM) inhibitor with a K_D of 6.6 μM. SMI-10B13 inhibits OSM-mediated STAT3 phosphorylation in T47D and MCF-7 cell lines (IC₅₀ = 136 and 164 nM, respectively). SMI-10B13 shows anti-tumor effect in human breast cancer mice models .

HY-128600

ERD-308 1 Publications Verification	PROTACs Estrogen Receptor/ERR	Cancer
ERD-308 is a potent estrogen receptor (ER) PROTAC degrader. ERD-308 has DC₅₀ values of 0.17 nM and 0.43 nM in MCF-7 and T47D ER+ cells. ERD-308 can inhibit the proliferation of breast cancer cells and exhibits anti-tumor activity. (Pink: Target Protein Ligand (HY-48027); Black: Linker (HY-172643); Blue: VHL Ligand (HY-112078); VHL Ligand+Linker：(HY-172645))

HY-148214

CDK2/4/6-IN-2	CDK	Cancer
CDK2/4/6-IN-2 is a selective CDK2/4/6 inhibitor with IC₅₀ values <1 μM. CDK2/4/6-IN-2 inhibits cells proliferation and phosphorylation of retinoblastoma protein at Ser807/811 in breast cancer cells. CDK2/4/6-IN-2 can be used for the research of cancer, such as breast cancer .

HY-124053

BRD2492	HDAC	Cancer
BRD2492 (compound 6d) is a potent, selective HDAC1 and HDAC2 inhibitor with IC₅₀s of 13.2 nM and 77.2 nM, respecrtively. BRD2492 exhibits >100-fold selectivity for HDAC1/2 over selectivity over HDAC3 and HDAC6. BRD2492 inhibits breast cancer cell lines growth with IC₅₀s of 1.01 μM and 11.13 μM for T-47D and MCF-7 cells, respectively .

HY-N4010

Iriflophenone	Others	Cancer
Iriflophenone, isolated from Aquilaria sinensis, stimulates MCF-7 and T-47D human breast cancer cells proliferation .

HY-120234

Z-LLNle-CHO Z-Leu-Leu-Nle-CHO; GSII	γ-secretase Proteasome Apoptosis	Cancer
Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia .

HY-P991358

XOMA-213 LFA-102; X213	Estrogen Receptor/ERR STAT Akt	Cancer
XOMA-213 (LFA-102; X213) is a human monoclonal antibody (mAb) targeting the prolactin receptor (PRLR), with a K_d value of 2 nM against the human target. XOMA-213 blocks PRL-induced cell proliferation and inhibits the activation of multiple PRLR ligands, including PRL and human growth hormone (hGH). XOMA-213 suppresses PRL-induced phosphorylation of Stat5, Akt and ERK1/2 in cells. XOMA-213 induces tumor regression, delays disease progression, and inhibits PRLR signaling as well as tumor growth. XOMA-213 can be used in research related to breast cancer .

HY-176184

PROTAC DDR1 degrader-1	PROTACs Discoidin Domain Receptor MMP	Cancer
PROTAC DDR1 degrader-1 is a potent and selective DDR1-targeting PROTAC degrader. PROTAC DDR1 degrader-1 selectively induces full-length DDR1 degradation via the ubiquitin proteasome system, blocking downstream signaling pathways. PROTAC DDR1 degrader-1 inhibits tumor cell migration and invasion. PROTAC DDR1 degrader-1 exhibits anti-tumor activity in mice. PROTAC DDR1 degrader-1 can be used for the research of DDR1-driven cancers .

HY-15668

ST09	MMP Bcl-2 Family Caspase Apoptosis Drug Derivative	Cancer
ST09 is an efficient and low toxicity Curcumin (HY-N0005) derivative. ST09 significantly inhibits cell migration and downregulates the expression of MMP1, MMP2, and Vimentin. ST09 has strong cytotoxicity to breast cancer cells, such as MDA-MB-231, MCF7 and T47D cells. ST09 induces cell apoptosis by upregulating Bax and cleaved caspase-3/9. ST09 can be used in the research of cancer such as breast cancer .

HY-172964

KIM-161	PI3K Akt mTOR Apoptosis Reactive Oxygen Species (ROS)	Cancer
KIM-161 is a PIK3CA inhibitor. KIM-161 has significant antiproliferative activity with IC₅₀ values of 1.428 and 1.562 µM against PI3KCA mutant breast cancer MCF7 and T47D cells, respectively. KIM-161 induces apoptosis and cell cycle arrest by inhibiting the PI3K/AKT/mTOR signaling pathway and inducing ROS production. KIM-161 can be used to study breast cancer and its PI3KCA mutant subtypes .

HY-157151

iPRMT1	Histone Methyltransferase	Cancer
iPRMT1 is a potent and selective PRMT1 inhibitor for breast cancer research. iPRMT1 inhibits breast cancer cell growth in vitro and in vivo with EC₅₀ values of 90, 70, and 9 nM in MCF7, T47D, and MDA-MB-231 cells, respectively .

HY-N15759

8,2'-Diprenylquercetin 3-methyl ether	Biochemical Assay Reagents	Cancer
8,2'-Diprenylquercetin 3-methyl ether is isolated from Sinopodophyllum hexandrum (Royle) Ying (Sinopodophylli Fructus). 8,2'-Diprenylquercetin 3-methyl ether is cytotoxic to MDA-231 and T47D breast cancer cell lines .

HY-174867

AY-4	PROTACs Ferroptosis	Cancer
AY-4 (Compound AY-4) is an efficient PROTAC degrader targeting FTH1 (K_d = 3.17 nM). AY-4 effectively upregulates the levels of ferrous (Fe ²⁺) and ferric (Fe ³⁺) ions in cells. AY-4 is a potential anticancer candidate compound that regulates iron homeostasis through ferritin degradation and enhances the efficacy of existing drugs. AY-4 can effectively reduce the level of FTH1 in breast cancer cells (Pink: FTH1 ligand AY-2 (HY-174871); Blue: E3 ligand Pomalidomide (HY-10984); Black: Linker, Pomalidomide-PEG3-acid (HY-174872)) .

HY-N4010R

Iriflophenone (Standard)	Reference Standards Others	Cancer
Iriflophenone, isolated from Aquilaria sinensis, stimulates MCF-7 and T-47D human breast cancer cells proliferation .

HY-151120

Anticancer agent 79	Others	Cancer
Anticancer agent 79 (compound 3d) shows good anti-breast cancer activity. Anticancer agent 79 shows good cytotoxic activity in T47-D cells, with an IC₅₀ of 13.64 ± 0.26 μM .

HY-155197

ER degrader 7	Microtubule/Tubulin Estrogen Receptor/ERR	Cancer
ER degrader 7 (Compound 35t) is an ERα and ERβ degrader. ER degrader 7 inhibits tubulin polymerization. ER degrader 7 inhibits cell viability with IC₅₀s of 0.06, 2.56, 15.84, 1.59, 1.67, 1.37 μM for MCF-7, T47D, MCF-10A, LCC2, T47D D538G, and T47D Y537S cells respectively. ER degrader 7 also inhibits breast cancer tumor growth .

HY-150543

Steroid sulfatase-IN-3	Steroid Sulfatase	Cancer
Steroid sulfatase-IN-3 (compound 1q) is a potent STS (Steroid sulfatase) inhibitor, with an IC₅₀ of 25.8 nM. Steroid sulfatase-IN-3 shows antiproliferative activity against T-47D estrogen-dependent breast cancer cells, with an IC₅₀ of 1.04 µM .

HY-155233

Steroid sulfatase-IN-5	Steroid Sulfatase	Cancer
Steroid sulfatase-IN-5 (compound 10b) is a steroid sulfatase (STS) inhibitor (IC₅₀: 0.32 nM). Steroid sulfatase-IN-5 inhibits T-47D cell proliferation with an IC₅₀ of 35.7 μM. Steroid sulfatase-IN-5 can be used for research of breast cancer .

HY-N13118

Sinopodophylline B	Others	Cancer
Sinopodophylline B (compound 2) is a flavonoid glycoside compound that is cytotoxic to breast cancer cells. For example, the IC₅₀ of Sinopodophylline B is 1.5 μM (T47D) and 44.2 μM (MDA-MB-231), respectively .

HY-178463

F0840-0093	Estrogen Receptor/ERR	Cancer
F0840-0093 is a highly selective estrogen receptor α (ERα) degrader. F0840-0093 exhibits potent antiproliferative activity against T47D cells with an IC₅₀ value of 4.65 μM. F0840-0093 is promising for research of estrogen receptor-positive (ER+) breast cancer .

HY-138089

17β-Hydroxy exemestane	Androgen Receptor Estrogen Receptor/ERR LDLR	Metabolic Disease Cancer
17β-Hydroxy exemestane (17-H-EXE) is the primary active metabolite of Exemestane (HY-13632). 17β-Hydroxy exemestane is an aromatase inhibitor (IC₅₀ = 69 nM) and an androgen receptor (AR) agonist (IC₅₀ = 39.6 nM) that is selective for AR over estrogen receptor α (ERα; IC₅₀ = 21.2 μM). 17β-Hydroxy exemestane stimulates growth of AR- and ERα-positive MCF-7 (EC₅₀= 2.7 μM) and T47D breast cancer cells (EC₅₀s = 0.43 and 1500 nM for AR- and ER-mediated growth, respectively) and inhibits proliferation of testosterone-treated aromatase-overexpressing MCF-7 cells. 17β-Hydroxy exemestane inhibits increases in serum cholesterol and LDL levels and prevents decreases in bone mineral density in the lumbar vertebrae and femur, as well as femoral bending strength and compressive strength of the fifth lumbar vertebrae in ovariectomized rats .

HY-179045

ERα degrader 14	Estrogen Receptor/ERR Apoptosis	Cancer
ERα degrader 14 (Compound B7) is a potent ERα degrader. ERα degrader 14 exhibits significantly potent and selective anti-proliferative activity on two ERα-positive breast cancer cell lines (MCF-7 and T47D). ERα degrader 14 induces cell cycle arrest, inhibits cell migration, and induces cell apoptosis. ERα degrader 14 effectively inhibits tumor growth in mouse models. ERα degrader 14 can be used for the study of breast cancer .

HY-123163

JNJ-1250132 RWJ-66826; RTI-6617-003	Progesterone Receptor Glucocorticoid Receptor Androgen Receptor Estrogen Receptor/ERR	Endocrinology Cancer
JNJ-1250132 (RWJ-66826) is an orally active and potent steroidal progesterone receptor (PR) antagonist, with an IC₅₀ of 1.3 nM. JNJ-1250132 inhibits binding of the receptor to DNA in vitro. JNJ-1250132 is a potent competitive inhibitor of binding to the human glucocorticoid receptor (GR) (IC₅₀=0.50 nM) and the rat androgen receptor (AR) (IC₅₀=5.6 nM), and was a weak inhibitor of binding to human Estrogen receptor (ER) (IC₅₀ >3000 nM) .

HY-169019

XJTU-L453	PI3K Apoptosis	Cancer
XJTU-L453 is a PI3Kα inhibitor with an IC₅₀ value of 0.4 nM. XJTU-L453 can inhibit the proliferation of breast cancer cell lines T47D and MCF7, with IC₅₀ values of 0.2 μM and 0.5 μM, respectively. XJTU-L453 can inhibit the PI3K pathway, induce cell cycle arrest, and trigger cell apoptosis (apoptosis). XJTU-L453 also has antitumor activity in MCF7 xenograft mice .

HY-125916

Pseurotin A	Endogenous Metabolite	Cancer
Pseurotin A is a secondary metabolite of Aspergillus and other fungi. Pseurotin A is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits IgE production (IC₅₀ = 3.6 μM). Pseurotin A inhibits the PCSK9-LDLr interaction. Pseurotin A shows dose-dependent reduction of PCSK9, along with increased LDLR levels in hormone-dependent breast cancer cell lines. Pseurotin A exhibits antitumor activity .

HY-P10393

ERα17p ERα (295-311)	Apoptosis	Cancer
ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .

HY-175292

EGFR WT/T790M-IN-3	EGFR Microtubule/Tubulin	Cancer
EGFR WT/T790M-IN-3 is an irreversible covalent EGFR ^WT and EGFR ^T790M inhibitor with IC₅₀s value of 28.1 and 24.6 nM. EGFR WT/T790M-IN-3 hampers tubulin polymerization through IC₅₀ value of 5.1 μM. EGFR WT/T790M-IN-3 shows significant anti-proliferative effects on HCT116 and T47D cells, with IC₅₀ values of 3.12 and 4.12 μM, respectively. EGFR WT/T790M-IN-3 can be used for the study of cancers such as non-small cell lung cancer, colon cancer and breast cancer .

HY-121149B

(E/Z)-Droloxifene (E/Z)-3-Hydroxytamoxifen	Estrogen Receptor/ERR Apoptosis	Cancer
(E/Z)-Droloxifene is a mixture of (E)-droloxifene (a selective estrogen receptor modulator) and (Z)-droloxifene. (E)-Droloxifene binds to the estrogen receptor (ER) with an IC₅₀ value of 24 nM in rabbit uterine homogenates. (E)-Droloxifene increases uterine weight in immature rats, and reduces estradiol-induced increases in uterine weight in juvenile rats. (E)-Droloxifene also inhibits 17β-estradiol-stimulated growth of MCF-7, ZR-75-1, and T47D human breast cancer cells. (Z)-Droloxifene binds weakly to ER and has no estrogenic or antiestrogenic activity .

HY-179688

PROTAC CDK2/4 Degrader-1	PROTACs CDK	Cancer
PROTAC CDK2/4 Degrader-1 (Compound 5) is a CDK2/4 PROTAC degrader, with its DC₅₀ values for CDK2 and CDK4 both ≤ 10 nM. PROTAC CDK2/4 Degrader-1 exhibits excellent inhibitory activity against cell proliferation in OVCAR3 and T47D cells. PROTAC CDK2/4 Degrader-1 can be used for research on breast cancer and ovarian cancer .

HY-19822S2

Elacestrant-d10 RAD1901-d₁₀	Estrogen Receptor/ERR Isotope-Labeled Compounds	Cancer
Elacestrant-d₁₀ is the deuterium labeled of Elacestrant (HY-19822). Elacestrant is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also inhibits growth of ER ⁺ breast cancer cell lines in vitro and in vivo .

HY-183285

PI3Kα-IN-32	PI3K Akt	Cancer
PI3Kα-IN-32 (Compound 11f) is a selective, orally active PI3Kα inhibitor, with an IC₅₀ of 26.3 nM against PI3Kα ^H1047R. PI3Kα-IN-32 inhibits AKT phosphorylation. PI3Kα-IN-32 exhibits anticancer activity against breast cancer. PI3Kα-IN-32 can be used in the research of HR ⁺/HER2 ^- breast cancer .

HY-182083

PROTAC PI3Kα/δ degrader-1	PROTACs PI3K	Cancer
PROTAC PI3Kα/δ degrader-1 is an orally active PI3Kα/δ PROTAC degrader, with an IC₅₀ of 0.34 nM for PI3Kα and 1.85 nM for PI3Kδ. PROTAC PI3Kα/δ degrader-1 inhibits the proliferation and migration of cancer cells, induces G1-phase cell cycle arrest and PI3Kα degradation. PROTAC PI3Kα/δ degrader-1 suppresses tumor growth in breast cancer xenograft mouse models. PROTAC PI3Kα/δ degrader-1 can be used for the research of breast cancer .

HY-183139

CD666	RAR/RXR AP-1	Cancer
CD666 is a selective retinoic acid receptor-γ (RAR-γ) agonist with a K_d of 68 nM. CD666 inhibits proliferation of cancer cells and shows synergistical effects and anti-AP-1 activity with IFN-γ. CD666 can be used for the research of breast cancer .

HY-181136

Antiestrogenic agent-1	Estrogen Receptor/ERR	Metabolic Disease Cancer
Antiestrogenic agent-1, an organophosphorus 13α-estrone derivative, is an antiestrogenic agent. Antiestrogenic agent-1 can disrupt estrogen signaling by inhibiting estrogen-mediated transcriptional activity. Antiestrogenic agent-1 can inhibit cancer cells proliferation, migration, invasion and induce G1-phase arrest. Antiestrogenic agent-1 mitigates estrogen-induced uterine growth in immature rats and inhibits tumor growth in a murine triple-negative breast cancer mice model. Antiestrogenic agent-1 can be used for the researches of cancer and endocrinology,such as breast cancer, oropharyngeal squamous cell carcinoma .

HY-183119

Legumain-IN-2	Legumain	Cancer
Legumain-IN-2 is a selective legumain inhibitor with a human legumain IC₅₀ of 0.9 nM. Legumain-IN-2 can be used for the research of breast cancer .

HY-181772

MCULE-3064932370	E1/E2/E3 Enzyme	Cancer
MCULE-3064932370 is a covalent and allosteric SUMO E1 (heterodimer of Aos1 and Uba2) inhibitor with IC₅₀ values ranging from 16.66 μM to 2.96 μM. MCULE-3064932370 inhibits SUMOylation of Uba2. MCULE-3064932370 has anti-cancer activity against breast cancer .

HY-181832

ASS1 activator 1	AMPK Apoptosis	Cancer
ASS1 activator 1 (Compound 10f) is a ASS1 activator with an EC₅₀ of 1.90 μM. ASS1 activator 1 enhances the activity of ASS1 and promotes AMPK phosphorylation. ASS1 activator 1 induces cell Apoptosis. ASS1 activator 1 exhibits anticancer activity against triple-negative breast cancer, colorectal cancer and liver cancer .

Cat. No.	Product Name	Target	Research Area